Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Racial/ethnic minorities underrepresented in Alzheimer’s neuroimaging research
Jul 28, 2023
Sample diversity has improved recently, with proportion of Blacks increasing from 3.39% in 1994-2017 to 8.29% in 2018-2022.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Minor neuropsychological deficits indicate risk for progression to Alzheimer’s disease
Oct 13, 2023
For patients with subjective cognitive decline, those with minor neuropsychological deficits have increased cognitive decline and a risk for progression to mild cognitive impairment.
Finger prick, venous blood can ID key Alzheimer’s disease biomarkers
Jul 20, 2023
Capillary and venous dry blood spot can identify glial fibrillary acidic protein, neurofilament light and phosphorylated tau.
Plasma biomarkers identified for detecting presymptomatic Alzheimer’s disease
Jan 13, 2023
Plasma P-tau181, NfL and GFAP concentrations were higher in mutation carriers versus noncarriers of autosomal dominant Alzheimer’s disease.
Experimental drug for Alzheimer’s disease slows decline in thinking
May 03, 2023
Eli Lilly says the drug slows memory and thinking declines in early symptomatic Alzheimer’s disease patients by more than a third.